In addition, several studies have suggested that PI3Kα inhibitors may exhibit synthetic lethality when used in combination with other anti-tumor therapies such as poly ADP-ribose polymerase (PARP) inhibitors34, BET inhibitors35, or fulvestrant15,32. This evidence concerns the gene DNER and neoplasm.